Repatha vs Amlodipine: Side-Effect Profile Head-to-Head

Why Comparing These Two Drugs Requires Context

Repatha and amlodipine sit in entirely different pharmacologic categories and target different cardiovascular risk factors. No randomized trial has ever compared them head to head, because doing so would not make clinical sense. They are not interchangeable.

Repatha (evolocumab) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing it from degrading LDL receptors on hepatocytes. The result is a dramatic drop in circulating LDL cholesterol. The FOURIER trial (N=27,564) demonstrated a 59% reduction in LDL-C and a 15% relative reduction in the primary composite cardiovascular endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) over a median follow-up of 2.2 years [1]. These patients all had established atherosclerotic cardiovascular disease (ASCVD) and were already on moderate- or high-intensity statin therapy.

Amlodipine belongs to the dihydropyridine calcium channel blocker class and reduces blood pressure by relaxing vascular smooth muscle. The ASCOT-BPLA trial (N=19,257) showed that an amlodipine-based regimen reduced fatal and nonfatal stroke by 23% and total cardiovascular events by 16% compared to an atenolol-based regimen in hypertensive patients with at least three additional cardiovascular risk factors [2]. The trial was stopped early because of the clear benefit in the amlodipine arm.

The comparison that matters here is not which drug is "better." It is understanding how each drug's side-effect burden might affect a patient who takes one, the other, or both.

Repatha Side Effects: What the Data Show

The most frequently reported adverse events with evolocumab are injection-site reactions, nasopharyngitis, and upper respiratory tract infections. None of these occurred at rates that dramatically exceeded placebo in large trials.

In FOURIER, the overall adverse-event rate was similar between evolocumab (78.4%) and placebo (78.0%), a gap too narrow to be clinically meaningful [1]. Injection-site reactions occurred in 2.1% of evolocumab-treated patients versus 1.6% on placebo. An open-label extension study (OSLER-1) reported injection-site reactions at approximately 5.7% over 11.1 months of follow-up, with most events classified as mild [3]. Nasopharyngitis appeared in about 10% of patients in pooled phase 3 analyses, though rates were comparable between drug and placebo groups.

Neurocognitive effects drew early attention. The EBBINGHAUS substudy of FOURIER specifically tested cognitive function in 1,974 patients using the Cambridge Neuropsychological Test Automated Battery and found no significant difference between evolocumab and placebo across any cognitive domain over a median of 19 months [4]. This is worth knowing because LDL-C levels dropped below 25 mg/dL in many participants, and the concern was that very low cholesterol could impair brain function. It did not.

Myalgia has been reported, but the rate does not exceed that of placebo when statin background therapy is held constant. Because all FOURIER patients were already on statins, any new muscle complaints could not easily be attributed to evolocumab alone. Dr. Marc Sabatine, lead investigator of FOURIER, stated: "The safety profile of evolocumab in FOURIER was reassuring, with no excess of serious adverse events, including muscle-related events, despite very low achieved LDL-C levels."

Allergic reactions and flu-like symptoms occur rarely. Discontinuation rates due to adverse events in FOURIER were 1.6% for evolocumab and 1.5% for placebo, confirming that tolerability was not a major issue [1].

Amlodipine Side Effects: What the Data Show

Amlodipine's side-effect profile is dominated by dose-dependent vasodilatory effects. Peripheral edema is the most common complaint and the one most likely to lead patients to discontinue the drug.

The prescribing information for amlodipine reports peripheral edema rates of 1.8% at 2.5 mg, 3.0% at 5 mg, and 10.8% at 10 mg, compared to 0.6% for placebo [5]. This edema is not caused by fluid retention in the traditional sense. It results from preferential arteriolar dilation without matching venodilation, which increases capillary hydrostatic pressure and drives fluid into interstitial tissue, particularly in the lower extremities. The edema is typically bilateral, pitting, and worse at the end of the day.

Other vasodilatory effects include flushing (reported in 0.7% to 3.4%), dizziness (1.1% to 3.4%), and palpitations (0.7% to 4.5%), all dose-dependent [5]. Headache occurs in approximately 7.3% of patients across dose ranges and was the most frequently reported adverse event in early trials, though placebo headache rates were also elevated.

Fatigue affected 4.5% of patients at the 10 mg dose. Nausea sits around 2.9%. Abdominal pain at 1.6%.

In ASCOT-BPLA, the amlodipine arm reported higher rates of peripheral edema (23%) compared to atenolol (6%), a difference that was expected given the known class effect of dihydropyridines [2]. Despite this, fewer patients on amlodipine developed new-onset diabetes (hazard ratio 0.70), which became one of the trial's most discussed secondary findings.

Dr. Peter Sever, ASCOT principal investigator, noted: "The metabolic neutrality of amlodipine, and indeed its association with a lower incidence of new-onset diabetes compared to atenolol, changed how we think about first-line antihypertensive selection."

A clinically significant but underappreciated side effect is gingival hyperplasia, reported in approximately 1% to 10% of patients on calcium channel blockers in dental literature reviews [6]. The overgrowth of gum tissue is reversible on discontinuation but can become uncomfortable and cosmetically distressing if the drug is continued long-term without dental monitoring.

Head-to-Head Side-Effect Comparison by Organ System

Because no direct comparison trial exists, this section organizes known adverse-event data from each drug's key trials and prescribing information by organ system.

Musculoskeletal. Myalgia is reported with both drugs but through different mechanisms. With evolocumab, muscle complaints in FOURIER did not exceed placebo rates (approximately 5% in both arms) [1]. With amlodipine, myalgia is listed at approximately 2% in the prescribing label. Patients already on statins who add Repatha should not expect a meaningful increase in muscle symptoms based on current evidence.

Cardiovascular. Amlodipine can cause dose-dependent hypotension, palpitations, and peripheral edema. Evolocumab has no direct hemodynamic effects. Neither drug prolonged the QTc interval in dedicated studies.

Gastrointestinal. Amlodipine is associated with nausea (2.9%) and abdominal pain (1.6%). Evolocumab's GI side effects in FOURIER were not statistically different from placebo.

Neurological. Dizziness occurs in up to 3.4% of amlodipine patients, usually in the first weeks as blood pressure adjusts. The EBBINGHAUS data cleared evolocumab of cognitive risk even at extremely low LDL-C levels [4].

Immunologic / injection-related. This category applies only to evolocumab. Injection-site erythema, pain, and bruising are the expected local reactions. Development of anti-drug antibodies occurred in fewer than 0.3% of patients across the evolocumab clinical program, and binding antibodies did not appear to affect efficacy or safety [7].

Dermatologic. Amlodipine rarely causes rash or pruritus (<1%). Evolocumab-related skin events beyond the injection site are uncommon.

Metabolic. Amlodipine is metabolically neutral regarding glucose and lipids. In ASCOT, it was associated with a 30% lower risk of developing new diabetes compared to atenolol [2]. Evolocumab has no known effect on glucose metabolism.

Who Gets Both Drugs, and What That Means for Side-Effect Burden

A patient with both hypertension and high LDL-C despite statin therapy may be prescribed amlodipine and evolocumab simultaneously. The 2018 AHA/ACC cholesterol guidelines recommend adding a PCSK9 inhibitor for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [8]. Blood pressure management in that same patient follows a separate algorithm.

Dual use does not create pharmacokinetic interactions. Evolocumab is cleared by the reticuloendothelial system as a monoclonal antibody. Amlodipine is metabolized by hepatic CYP3A4. Their metabolic pathways do not intersect.

The combined side-effect load is therefore additive, not synergistic. A patient might experience ankle swelling from amlodipine and mild injection-site redness from evolocumab. These are unrelated events managed independently.

The practical clinical concern is adherence. A patient who dislikes biweekly injections and also has uncomfortable peripheral edema from amlodipine may struggle with both. Switching amlodipine to another antihypertensive class (an ACE inhibitor or ARB) can resolve the edema without sacrificing blood pressure control. Evolocumab also offers a monthly 420 mg autoinjector option for patients who want fewer injections, which was shown to produce equivalent LDL-C lowering in FOURIER dosing substudies [1].

Cost and Access as Practical Side-Effect Modifiers

Side effects exist in context. A drug that costs $5,850 per year (Repatha's US list price before copay assistance) generates a different risk-benefit conversation than one available as a generic for under $15 per month (amlodipine).

According to FDA approval records, evolocumab was approved in August 2015 for homozygous familial hypercholesterolemia and clinical ASCVD [9]. Its use has expanded as cardiovascular outcome data matured, but insurers frequently require prior authorization and documentation of statin intolerance or inadequate response before coverage.

Amlodipine, approved in 1987, lost patent protection years ago. Generic amlodipine besylate is on the WHO Model List of Essential Medicines and is available in virtually every pharmacy worldwide [10].

This cost difference does not change the pharmacology of either drug's side effects, but it does change how patients and clinicians weigh tolerability. A patient experiencing mild injection-site discomfort from a drug costing several thousand dollars annually may view that side effect differently than mild ankle swelling from a drug costing pennies per day.

Discontinuation Rates and Long-Term Safety

Long-term safety data favor both drugs, though the evidence base for amlodipine is decades deeper.

Evolocumab's open-label extension data out to five years (OSLER-1 extension) showed no new safety signals, with serious adverse event rates remaining stable and consistent with the controlled trial period [3]. Injection-site reactions did not increase over time. The median achieved LDL-C of 30 mg/dL was maintained without evidence of hepatotoxicity, rhabdomyolysis, or neurocognitive decline over the extended follow-up.

Amlodipine has post-marketing safety data stretching back more than three decades. The most significant long-term concern is the dose-dependent edema, which does not resolve spontaneously and requires either dose reduction, addition of an ACE inhibitor or ARB (which reduce the edema through venodilation), or drug discontinuation. The ACCOMPLISH trial (N=11,506) provided useful 36-month data showing that combining amlodipine with benazepril reduced both cardiovascular events and the edema burden compared to amlodipine monotherapy [11].

Drug discontinuation rates tell a clean story. In FOURIER, 1.6% of patients stopped evolocumab due to adverse events [1]. In pooled amlodipine trials, discontinuation for side effects ranged from 1.5% at 5 mg to 3.0% at 10 mg [5]. Both drugs are well tolerated relative to the cardiovascular risk they address.

Choosing Based on Side-Effect Tolerance

The decision between Repatha and amlodipine is not a choice between alternatives. These drugs treat different conditions. A patient with isolated hypertension does not need evolocumab. A patient with isolated hypercholesterolemia does not need amlodipine. But understanding each drug's side-effect profile helps clinicians anticipate and manage adverse events in the large population of patients who carry both risk factors.

For patients who are needle-averse, the biweekly or monthly injection schedule of evolocumab is a real barrier that should be discussed before prescribing. For patients prone to lower-extremity swelling, amlodipine 10 mg may cause enough discomfort to warrant starting at 5 mg or selecting a different antihypertensive. The 2017 ACC/AHA hypertension guidelines list thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers as first-line agents, giving clinicians alternatives when amlodipine's side effects are limiting [12].

Start amlodipine at 5 mg daily and titrate to 10 mg only if blood pressure targets are not met within 7 to 14 days. Initiate evolocumab at 140 mg subcutaneously every two weeks, drawing baseline LDL-C four to eight weeks after the first injection to confirm response.